Literature DB >> 8114616

Phosphorylation of neuromodulin in rat striatum after acute and repeated, intermittent amphetamine.

M E Gnegy1, P Hong, S T Ferrell.   

Abstract

Repeated, intermittent treatment of rats with amphetamine results in a sensitization of locomotor and stereotyped behaviors that is accompanied by an enhancement in stimulus-induced dopamine release. Increased phosphorylation of the neural specific calmodulin-binding protein, neuromodulin (GAP-43, B-50, F1) has been demonstrated in other forms of synaptic plasticity and plays a role in neurotransmitter release. To determine whether neuromodulin phosphorylation was altered during amphetamine sensitization, the in vivo phosphorylated state of neuromodulin was examined in rat striatum in a post hoc phosphorylation assay. Female, Holtzman rats received saline or 2.5 mg/kg amphetamine twice weekly for 5 weeks. One week after the last dose of amphetamine, rats were challenged with either 1 mg/kg or 2.5 mg/kg amphetamine or saline and the rats were sacrificed 30 min later. Purified synaptic plasma membranes were prepared in the presence of EGTA and okadaic acid to inhibit dephosphorylation, and were subsequently phosphorylated in the presence of purified protein kinase C and [gamma-32P]ATP. The protein kinase C-mediated post hoc phosphorylation of neuromodulin was significantly reduced in groups that received either acute or repeated amphetamine suggesting that neuromodulin in those groups contained more endogenous phosphate. The acute, challenge dose of amphetamine increased neuromodulin phosphorylation in the saline-treated controls but not in the repeated amphetamine-pretreated group. Anti-neuromodulin immunoblots showed no change in neuromodulin levels in any group. There was no significant change in protein kinase C activity in any treatment group. To further investigate the effect of acute amphetamine, the ability of amphetamine to alter neuromodulin phosphorylation in 32Pi-preincubated Percoll-purified rat striatal synaptosomes was examined. Amphetamine (10 microM) significantly increased phosphorylation of a 53 kDa band that migrated with authentic neuromodulin in the synaptosomes by 22% while 500 nM 12-O-tetradecanoylphorbol 13-acetate (TPA) increased neuromodulin phosphorylation by 45%. These data suggest that one injection of amphetamine can increase neuromodulin phosphorylation in rat striatum and that this increase is maintained for at least 1 week following a repeated, sensitizing regimen of amphetamine. Since sensitization can be induced with one dose of amphetamine, it is possible that enhanced neuromodulin phosphorylation could contribute to neurochemical events leading to enhanced release of dopamine and/or behavioral sensitization.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8114616     DOI: 10.1016/0169-328x(93)90055-t

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  10 in total

Review 1.  Tamoxifen use for the management of mania: a review of current preclinical evidence.

Authors:  Fernanda Armani; Monica Levy Andersen; José Carlos Fernandes Galduróz
Journal:  Psychopharmacology (Berl)       Date:  2014-01-18       Impact factor: 4.530

Review 2.  Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics.

Authors:  Rosilla F Bachmann; Robert J Schloesser; Todd D Gould; Husseini K Manji
Journal:  Mol Neurobiol       Date:  2005-10       Impact factor: 5.590

3.  Mood stabilizer psychopharmacology.

Authors:  Todd D Gould; Guang Chen; Husseini K Manji
Journal:  Clin Neurosci Res       Date:  2002-11-14

4.  Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms.

Authors:  Alan G Mallinger; Michael E Thase; Roger Haskett; Joan Buttenfield; David A Luckenbaugh; Ellen Frank; David J Kupfer; Husseini K Manji
Journal:  Bipolar Disord       Date:  2008-12       Impact factor: 6.744

Review 5.  A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder.

Authors:  Nancy DiazGranados; Carlos A Zarate
Journal:  Curr Psychiatry Rep       Date:  2008-12       Impact factor: 5.285

6.  Inbred C57BL/6J and DBA/2J mouse strains exhibit constitutive differences in regional brain fatty acid composition.

Authors:  Robert K McNamara; Jessica Able; Ronald Jandacek; Therese Rider; Patrick Tso
Journal:  Lipids       Date:  2008-10-16       Impact factor: 1.880

7.  Decreased phosphorylation of GAP-43/B-50 in striatal synaptic plasma membranes after circling motor activity.

Authors:  G C Paratcha; G R Ibarra; R Cabrera; J M Azcurra
Journal:  Neurochem Res       Date:  1998-10       Impact factor: 3.996

8.  Comparative peptidomics analysis of neural adaptations in rats repeatedly exposed to amphetamine.

Authors:  Elena V Romanova; Ji Eun Lee; Neil L Kelleher; Jonathan V Sweedler; Joshua M Gulley
Journal:  J Neurochem       Date:  2012-09-03       Impact factor: 5.372

Review 9.  Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder.

Authors:  Carlos A Zarate; Husseini K Manji
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

10.  Effect of Tamoxifen and Lithium on Treatment of Acute Mania Symptoms in Children and Adolescents.

Authors:  Elham Fallah; Sorror Arman; Mostafa Najafi; Bahar Shayegh
Journal:  Iran J Child Neurol       Date:  2016
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.